Pacira BioSciences merger converts CEO shares at $36.50
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacira BioSciences, Inc. completed its merger effective November 17, 2026. CEO Frank D. Lee’s 660,830.841 reported common shares, including RSUs and 1,022.077 shares acquired under the Employee Stock Purchase Plan, converted into a right to receive the $36.50-per-share offer price, net of applicable withholding taxes and without interest.
Lee’s 692,512 options, with a $32.07 exercise price, were canceled and converted into a cash right based on any excess of the offer price over the exercise price, subject to withholding. Lee reported zero shares and options afterward; Pacira continued as a wholly owned subsidiary of Viatris.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) F4 | 692,512 | -- | -- |
| Disposition | Common Stock F1, F2, F3 | 660,830.841 | $36.50 | $24.12M |
Footnotes (4)
- F1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
- F2. Includes 1,022.077 Shares acquired under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan in June 2026.
- F3. Includes restricted stock unit awards ("RSUs"). Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
- F4. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Key Figures
Key Terms
cash tender offer regulatory
Offer Price financial
restricted stock unit awards financial
Employee Stock Purchase Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What happened to Frank D. Lee’s PCRX options in the merger?
AI-generated analysis. How Rhea-AI works. Not financial advice.